Researchers at University of California, Irvine, have developed glycan-dependent T cell recruiters (GlyTRs) that target tumor-associated carbohydrate antigens safely and effectively across multiple cancer types. These engineered bispecific molecules engage T cells specifically at tumor sites without harming healthy tissues, addressing limitations of traditional immunotherapies that target protein antigens. Preclinical studies show promise in treating cancers including breast, colon, lung, ovarian, pancreatic, and prostate, representing a significant leap forward in pan-cancer immunotherapy.